A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral DensityRobert R. Recker, Stephen L. Myers, Toshio Matsumoto et al.|Journal of Bone and Mineral Research|2014Cited by 291
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimensJuan P. Frías, Deborah A. Robins|Diabetes Obesity and Metabolism|2020Cited by 204